| Literature DB >> 30971317 |
Maxime Cambournac1, Isabelle Goy-Thollot2, Julien Guillaumin3, Jean-Yves Ayoub4, Céline Pouzot-Nevoret2, Anthony Barthélemy2, Jeanne-Marie Bonnet-Garin4.
Abstract
BACKGROUND: Veterinary studies describing acute kidney injury (AKI) management using renal replacement therapy (RRT) are limited and have primarily focused on intermittent haemodialysis in North American populations. European data are lacking, although differences in populations, pathogen and toxin exposure and RRT modalities may exist between Europe and North America. The present study reviewed RRT-managed cases from the intensive care unit (ICU) of VetAgro Sup, Lyon, France, for the period 2012-2015. The aims were to describe a 4-h RRT protocol of intermittent low efficiency haemodiafiltration, population characteristics and outcomes in canine AKI cases requiring RRT and to identify prognostic variables. We defined DeltaCreat/h as the difference between the serum creatinine level after RRT treatment N and that before treatment N + 1 divided by the time between treatments (in hours).Entities:
Keywords: Acute renal failure; Outcome; Prognostic factors; Renal replacement therapy; Urinary output
Mesh:
Year: 2019 PMID: 30971317 PMCID: PMC6457005 DOI: 10.1186/s13028-019-0452-6
Source DB: PubMed Journal: Acta Vet Scand ISSN: 0044-605X Impact factor: 1.695
Description of demographic and laboratory data (median and range) for 39 dogs with acute kidney injury and comparison between survivors and non-survivors
| All (n = 39) | Survivors (n = 21) | Non-survivors (n = 18) | P | |
|---|---|---|---|---|
| Demographics | ||||
| Age (years) | 4.4 (0.25–15) | 4 (0.25–9.8) | 5.4 (0.3–15) | 0.04* |
| BW (kg) | 26.6 (6.7–69) | 30.8 (6.9–69) | 24 (6.7–67) | 0.30 |
| Male (%) | 26 (66%) | 15 (71%) | 11 (61%) | 0.48 |
| Laboratory data at admission | ||||
| BUN (mmol/L) | 52 (17.5–97.4) | 46.4 (17.5–82.1) | 56.8 (37.2–97.4) | 0.43 |
| Creat (µmol/L) | 790 (235–1951) | 785 (235–1682) | 927 (260–1951) | 0.16 |
| ALT (IU/L) | 137 (38–1739) | 145.5 (38–1705) | 127 (42–1739) | 0.48 |
| AlkP (IU/L) | 84 (26–416) | 81 (26–416) | 85 (36–416) | 0.85 |
| Total protein (g/dL) | 54 (33–81) | 55 (33–81) | 54 (38–69) | 0.69 |
| Na+ (mmol/L) | 152 (135–178) | 150 (135–178) | 152 (135–176) | 0.56 |
| K+ (mmol/L) | 4.7 (2.7–9.1) | 4.4 (2.7–9.1) | 4.9 (3.4–7.9) | 0.10 |
| Cl− (mmol/L) | 112 (98–127) | 112 (100–125) | 111.5 (98–127) | 0.80 |
| pH | 7.32 (7.02–7.52) | 7.34 (7.02–7.52) | 7.29 (7.07–7.41) | 0.21 |
| pCO2 (mmHg) | 34 (22–52) | 36 (23–50) | 33 (22–52) | 0.71 |
| HCO3− (mmol/L) | 17.15 (7.8–27.5) | 18.1 (10.3–27.5) | 17.1 (7.8–23) | 0.35 |
| Anion gap | 27.4 (17–49.3) | 25.4 (17–34.8) | 29 (21.9–49.3) | 0.01* |
BW body weight, BUN blood urea nitrogen, Creat creatinine, ALT alanine amino transferase, AlkP alkaline phosphatase
*Significant difference between survivors and non-survivors
Medical data (median and range) for 39 dogs with acute kidney injury and comparison between survivors and non-survivors
| All (n = 39) | Survivors (n = 21) | Non-survivors (n = 18) | P | |
|---|---|---|---|---|
| Medical data | ||||
| Aetiology | ||||
| Leptospirosis | 29 (74%) | 16 (76%) | 13 (72%) | |
| Intoxication | 6 (15%) | 3 (14%) | 3 (18%) | |
| Other | 4 (10%) | 2 (10%) | 2 (11%) | |
| Time to referral (days) | 4 (0–31) | 5 (2–31) | 3 (0–12) | 0.1 |
| Hosp. length (days) | 8 (1–23) | 10 (4–23) | 4 (1–14) | < 0.001* |
| RRT data | ||||
| Time to initiation (days) | 18 (4–72) | 18 (6–48) | 18 (4–72) | 0.7 |
| Number of RRT treatments | 3 (1–8) | 2 (1–8) | 3 (1–7) | 0.32 |
| DeltaCreat/h (1, 2) | 5.7 (− 13.5 to 71.8) | 0.8 (− 13.5 to 29.9) | 10.7 (− 10.7 to 71.8) | 0.002* |
| DeltaCreat/h (2, 3) | 14 (− 100 to 117) | 2 (− 100 to 82) | 28 (− 49 to 117) | 0.04* |
| DeltaCreat/h (3, 4) | − 2 (− 104; 100) | − 8 (− 61 to 5) | 4 (− 104; 100) | 0.05* |
| UOP at adm. | ||||
| Anuric | 13 (35.1%) | 4 (10.8%) | 9 (24.3%) | 0.015* |
| Non-anuric | 24 (64.9%) | 18 (48.6%) | 6 (16.2%) | 0.015* |
| UOP (mL/kg/h) in hosp. | ||||
| Day 1 (n = 37) | 0.5 (0–10) | 0.5 (0–10) | 0 (0–2) | 0.02* |
| Day 2 (n = 37) | 1.8 (0–16.3) | 2.4 (0–16.3) | 0.2 (0–3) | < 0.0001* |
| Day 3 (n = 36) | 1.95 (0–14.2) | 3 (0–12) | 0.3 (0–2.29) | < 0.0001* |
| Day 4 (n = 30) | 2.8 (0–12) | 3 (7–12) | 0.4 (0–4) | < 0.0001* |
| Day 5 (n = 28) | 3.2 (0–7.5) | 3.1 (1–7.5) | 0.4 (0–4) | 0.0003* |
RRT: extracorporeal renal replacement therapy. UOP at adm.: urine output at admission, with anuria defined as UOP < 0.3 mL/kg/h. DeltaCreat/h (1–2), (2, 3) and (3, 4): difference between serum creatinine concentration in µmol/L/h after the first and before the second, after the second and before the third, and after the third and before the fourth RRT treatment, respectively, divided by the time (in hours) between treatments. UOP in hosp.: daily urine output during hospitalization. Hosp. length: hospitalization length, in days
*Significant difference between survivors and non-survivors
Summary of significant prognostic factors’ characteristics identified in the multivariate analysis
| Parameter | Odds ratio | 95% Wald confidence interval | ||
|---|---|---|---|---|
| Number of RRT treat. | 5.1 | 1.65 | 16 | |
| Hospitalization length | 0.4 | 0.2 | 0.7 | |
Number of RRT treat.: number of extracorporeal renal replacement therapy (RRT) treatments. UOP (day 3): median urinary output at day 3. K (day 2): serum potassium concentration at day 2. DeltaCreat/h (1–2): difference between serum creatinine concentration in µmol/L/h after the first and before the second RRT treatment divided by the time (in hours) between the 2 treatments
Fig. 1Daily urine output (median ± range) for survivors (dotted line, circle mark) and non-survivors (broken line, triangle mark). *Significant difference; ✝predictive capacity
Fig. 2Repartition of AKI grade in 39 dogs with acute kidney injury at admission and at discharge for survivors (20 dogs) using the International Renal Interest Society (see footnote 1) classification. Grade I: creatinine < 140 µmol/L; Grade II: 141 < creatinine < 220 µmol/L; Grade III: 221 < creatinine < 439 µmol/L; Grade IV: 440 < creatinine < 880 µmol/L; Grade V: creatinine > 880 µmol/L
Fig. 3Daily serum creatinine concentration (median) for survivors (dotted line, circle mark) and non-survivors (broken line, triangle mark) during hospitalization. *Significant difference; ✝predictive capacity in DeltaCreat/h, defined as the difference between serum creatinine after RRT treatment N and before treatment N + 1 divided by the time (in hours) between the 2 treatments